Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval SummaryKatherine A. Thornton, Richard Pazdur, Geoffrey Kim et al.|Clinical Cancer Research|2012Cited by 149
FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspectiveJane P. F. Bai, Hao Zhu, Brian J. Schmidt et al.|The AAPS Journal|2021Cited by 38
Proceedings of a Workshop: Precision Dosing: Defining the Need and Approaches to Deliver Individualized Drug Dosing in the Real‐World SettingKimberly Maxfield, Issam Zineh, Yaning Wang et al.|Clinical Pharmacology & Therapeutics|2020Cited by 23
Model-Informed Approach Supporting Approval of Adalimumab (HUMIRA) in Pediatric Patients with Ulcerative Colitis from a Regulatory PerspectiveRuo‐Jing Li, Yaning Wang, Lian Ma et al.|The AAPS Journal|2022Cited by 9